WT1 and chronic myelogenous leukemia, BCR-ABL1 positive: High levels of WT1 expression were originally found to be associated with poor prognosis in adult AML patients and used as a marker for the detection of minimal residual disease in AML (Inoue et al, 1994), as well as in acute lymphoblastic (ALL) (Inoue et al, 1994) and chronic myeloid leukaemia (CML) (Inoue et al, 1996).